Analysts Endorse Ranbaxy-Pfizer Deal On Lipitor
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Analysts have backed the settlement deal between Ranbaxy Laboratories and Pfizer on the latter's blockbuster cholesterol-lowering drug Lipitor (atorvastatin) calling it a "very positive" development for the Indian drug maker
You may also be interested in...
Ranbaxy’s First-To-File ANDAs At Risk In FDA Data Integrity Probe
Several first-to-file ANDAs are on the line for Ranbaxy as it tries to resolve data integrity issues at its Paonta Sahib facility with U.S. FDA
Ranbaxy’s First-To-File ANDAs At Risk In FDA Data Integrity Probe
Several first-to-file ANDAs are on the line for Ranbaxy as it tries to resolve data integrity issues at its Paonta Sahib facility with U.S. FDA
Ranbaxy Sees Light At The End Of DoJ Investigation Tunnel - CEO Interview
MUMBAI - India's largest drug maker Ranbaxy is confident that the U.S. Department of Justice will soon withdraw its motion filed against the company, Ranbaxy CEO Malvinder Singh said in an interview with PharmAsia News